SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: BigKNY3 who wrote (21768)5/9/1999 11:43:00 PM
From: Edderd  Respond to of 23519
 
BigK
Good to have you back for a little spice. VLAD is fixated on the PCP and I can tell you again that it is too time consuming for the PCP to introduce MUSE to the patient and test dose him. I think that is why Vivus is doing a limited marketing to Urologists and probably effectively. The PCP will prescribe a pill with ease but the education and training just takes too much time. If the E&t isn't dome the failure rate is high. Alibra will definitely be much easier to market. There is still a market out there and those marginally effective oral meds in the works aren't going to cover it all.
All IMO
Ed



To: BigKNY3 who wrote (21768)5/9/1999 11:48:00 PM
From: Mkilloran  Respond to of 23519
 
BigKNY3...the CFO in a small company like VVUS has alot more input to the running of a company than in a large organization.

Vivus has great R&D for a small bio tech firm, good expense controls are in place now, marketing overseas is in place and expanding as Muse is launched in additional countries...

The missing link is a domestic partner to market MUSE and the newer products that Vivus is in the process of developing...

The link will be closed in time.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News